<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="34745c71-cfe8-172a-e063-6394a90adc67"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MEROPENEM FOR INJECTION safely and effectively. See full prescribing information for MEROPENEM FOR INJECTION
 <br/>
      <br/>
MEROPENEM for injection, for intravenous use
 <br/>
      <br/>
Initial U.S. Approval:1996
</title>
   <effectiveTime value="20250430"/>
   <setId root="0d37e43b-ff8d-495d-b9af-4fd5fce53d56"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="005387188"/>
            <name>Sandoz Inc</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="34889640-1105-4bce-e063-6394a90a323c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0781-3000" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MEROPENEM</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MEROPENEM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="45P3261C7T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="20"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="FV9J3JU8B1" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEROPENEM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YOP6PX0BAO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEROPENEM ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0781-3000-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0781-3000-95" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0781-3000-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0781-3000-96" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206086" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160829"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0781-3098" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MEROPENEM</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MEROPENEM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="45P3261C7T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CARBONATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="1"/>
                              <denominator unit="mL" value="30"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="FV9J3JU8B1" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEROPENEM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YOP6PX0BAO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEROPENEM ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0781-3098-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0781-3098-95" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0781-3098-94" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0781-3098-96" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20160829"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206086" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160829"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Lcb41e376-6647-4d9f-8df5-76fe10e09670">
               <id root="34745c71-cfe9-172a-e063-6394a90adc67"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <text>
                  <paragraph>Warnings and Precautions</paragraph>
                  <paragraph>Severe Cutaneous Adverse Reactions (5.2)                        6/2018</paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions, Rhabdomyolysis
 
    <linkHtml href="#S5.2">(5.3)</linkHtml>                       12/2024

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L941dc359-80a6-43e2-a49e-46e0e5d550a2">
               <id root="34745c71-cfea-172a-e063-6394a90adc67"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text/>
               <effectiveTime value="20250208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Meropenem for injection is a penem antibacterial indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (
  
     <linkHtml href="#S1.1">1.1</linkHtml>)
 
    </item>
                           <item>Complicated intra-abdominal infections (adult and pediatric patients). (
  
     <linkHtml href="#S1.2">1.2</linkHtml>)
 
    </item>
                           <item>Bacterial meningitis (pediatric patients 3 months of age and older only). (
  
     <linkHtml href="#S1.3">1.3</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="34745c71-cfeb-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only)</title>
                     <text>
                        <paragraph>Meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to
 
  <content styleCode="italics">Staphylococcus aureus </content>(methicillin-susceptible isolates only),
 
  <content styleCode="italics">Streptococcus pyogenes, Streptococcus agalactiae</content>, viridans group streptococci,
 
  <content styleCode="italics">Enterococcus faecalis </content>(vancomycin-susceptible isolates only),
 
  <content styleCode="italics">Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus </content>species
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="34745c71-cfec-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Complicated Intra-abdominal Infections (Adult and Pediatric Patients)</title>
                     <text>
                        <paragraph>Meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci,
 
  <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus </content>species
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="34745c71-cfed-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only)</title>
                     <text>
                        <paragraph>Meropenem for injection is indicated for the treatment of bacterial meningitis caused by
 
  <content styleCode="italics"> Haemophilus influenzae</content>, and
 
  <content styleCode="italics">Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae.</content>
                        </paragraph>
                        <paragraph>Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.</paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="Lae69d183-f8f6-4612-9f5c-c44a68b3d166">
                     <id root="34745c71-cfee-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection and other antibacterial drugs, meropenem for injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="34745c71-cfef-172a-e063-6394a90adc67"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by
  
     <content styleCode="italics">Pseudomonas aeruginosa</content>, a dose of 1 gram every 8 hours is recommended. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>Dosage should be reduced in adult patients with renal impairment. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                        </list>
                        <table border="1" cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr>
                                 <td colspan="3" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Creatinine Clearance (mL/min)</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose (dependent on type of infection)</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dosing Interval</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Greater than 50</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal)</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>26-50</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Recommended dose</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 12 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>10-25</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>One-half recommended dose</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 12 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Less than 10</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>One-half recommended dose</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 24 hours</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph>Pediatric patients 3 months of age and older</paragraph>
                        <table border="1" cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr>
                                 <td colspan="4" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function</content>
                                       <linkHtml href="#S2.3">(2.3)</linkHtml>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Type of Infection</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose (mg/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Up to a Maximum Dose</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dosing Interval</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Complicated skin and skin structure*</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Intra-abdominal</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>1 gram</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Meningitis</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>40</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>2 gram</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" valign="top">
                                    <paragraph>- Intravenous infusion is to be given over approximately 15 minutes to 30 minutes.</paragraph>
                                    <paragraph>- Intravenous bolus injection (5 mL to 20 mL) is to be given over approximately 3 minutes to 5 minutes.</paragraph>
                                    <paragraph>- There is no experience in pediatric patients with renal impairment.</paragraph>
                                    <paragraph>*20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended when treating complicated skin and skin structure infections caused by
     
        <content styleCode="italics">P. aeruginosa.</content>
                                       <linkHtml href="#S2.3">(2.3)</linkHtml>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph>Pediatric patients less than 3 months of age</paragraph>
                        <table border="1" cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr>
                                 <td colspan="3" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients Less than 3 Months of Age with Complicated Intra-Abdominal Infections and Normal Renal Function</content>
                                       <linkHtml href="#S2.3">(2.3)</linkHtml>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Age Group</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose (mg/kg)</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose Interval</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Infants less than 32 weeks GA and PNA less than 2 weeks</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 12 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Infants less than 32 weeks GA and PNA 2 weeks and older</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Infants 32 weeks and older GA and PNA less than 2 weeks</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>20</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Infants 32 weeks and older GA and PNA 2 weeks and older</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>30</paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>Every 8 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top">
                                    <paragraph>- Intravenous infusion is to be given over 30 minutes.</paragraph>
                                    <paragraph>- There is no experience in pediatric patients with renal impairment.</paragraph>
                                    <paragraph>GA: gestational age and PNA: postnatal age</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="34745c71-cff0-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adult Patients</title>
                     <text>
                        <paragraph>The recommended dose of meropenem for injection is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by
 
  <content styleCode="italics">P.aeruginosa</content>, a dose of 1 gram every 8 hours is recommended.

 </paragraph>
                        <paragraph>Meropenem for injection should be administered by intravenous infusion over approximately 15 minutes to 30 minutes. Doses of 1 gram may also be administered as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="34745c71-cff1-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Use in Adult Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See
 
  <linkHtml href="#Dose1">dosing Table 1</linkHtml> below.)

 </paragraph>
                        <paragraph>When only serum creatinine is available, the following formula (Cockcroft and Gault equation)
 
  <sup>1</sup>may be used to estimate creatinine clearance.

 </paragraph>
                        <paragraph>Males: Creatinine Clearance (mL/min) =</paragraph>
                        <paragraph>
                           <content styleCode="underline">Weight (kg) × (140 - age)</content>
                           <br/>  72 × serum creatinine (mg/dL)

 </paragraph>
                        <paragraph>Females: 0.85 × above value</paragraph>
                        <paragraph>
                           <br/>
                           <content styleCode="bold">Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients with Renal Impairment</content>
                        </paragraph>
                        <table ID="Dose1" width="75%">
                           <col width="30%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <thead>
                              <tr styleCode="First Last">
                                 <th align="left" styleCode="Lrule">Creatinine Clearance 
     <br/>  (mL/min)
    </th>
                                 <th align="left">Dose (dependent on type of infection)</th>
                                 <th align="left" styleCode="Rrule">Dosing Interval</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule">Greater than 50</td>
                                 <td align="left">Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal)</td>
                                 <td align="left" styleCode="Rrule">Every 8 hours</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">26-50</td>
                                 <td align="left">Recommended dose</td>
                                 <td align="left" styleCode="Rrule">Every 12 hours</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">10-25</td>
                                 <td align="left">One-half recommended dose</td>
                                 <td align="left" styleCode="Rrule">Every 12 hours</td>
                              </tr>
                              <tr styleCode="Botrule Last">
                                 <td align="left" styleCode="Lrule">Less than 10</td>
                                 <td align="left">One-half recommended dose</td>
                                 <td align="left" styleCode="Rrule">Every 24 hours</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="34745c71-cff2-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Use in Pediatric Patients</title>
                     <effectiveTime value="20191201"/>
                     <component>
                        <section>
                           <id root="34745c71-cff3-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Patients 3 Months of Age and Older</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>For pediatric patients 3 months of age and older, the Meropenem for Injection dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (cSSSI, cIAI, intra-abdominal infection or meningitis). See
  
   <linkHtml href="#Dose2">dosing Table 2</linkHtml> below.
 
  </item>
                                 <item>For pediatric patients weighing over 50 kg administer meropenem for injection at a dose of 500 mg every 8 hours for cSSSI, 1 gram every 8 hours for cIAI and 2 grams every 8 hours for meningitis.</item>
                                 <item>Administer meropenem for injection as an intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.</item>
                                 <item>There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.</item>
                              </list>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table 2: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function</content>
                              </paragraph>
                              <table ID="Dose2" width="75%">
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="15%" align="left" valign="top"/>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th align="left" styleCode="Lrule">Type of Infection</th>
                                       <th align="center">Dose (mg/kg)</th>
                                       <th align="center">Up to a Maximum Dose</th>
                                       <th align="left" styleCode="Rrule">Dosing Interval</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="left" styleCode="Lrule">Complicated skin and skin structure infections</td>
                                       <td align="center">10</td>
                                       <td align="center">500 mg</td>
                                       <td align="left" styleCode="Rrule">Every 8 hours</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Complicated intra-abdominal infections</td>
                                       <td align="center">20</td>
                                       <td align="center">1 gram</td>
                                       <td align="left" styleCode="Rrule">Every 8 hours</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule">Meningitis</td>
                                       <td align="center">40</td>
                                       <td align="center">2 grams</td>
                                       <td align="left" styleCode="Rrule">Every 8 hours</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There is no experience in pediatric patients with renal impairment.</paragraph>
                              <paragraph>When treating cSSSI caused by
 
  <content styleCode="italics">P. aeruginosa</content>, a dose of 20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-cff4-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Pediatric Patients Less Than 3 Months of Age</content>
                              </paragraph>
                              <paragraph>For pediatric patients (with normal renal function) less than 3 months of age, with complicated intra-abdominal infections, the meropenem for injection dose is based on gestational age (GA) and postnatal age (PNA). See
 
  <linkHtml href="#Dose3">dosing Table 3</linkHtml> below.

 </paragraph>
                              <paragraph>Meropenem for injection should be given as intravenous infusion over 30 minutes.</paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table 3: Recommended Meropenem for Injection Dosage Schedule for Pediatric Patients Less than 3 Months of Age with Complicated Intra-abdominal Infections and Normal Renal Function</content>
                              </paragraph>
                              <table ID="Dose3" width="75%">
                                 <col width="50%" align="left" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <col width="15%" align="left" valign="middle"/>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th align="left" styleCode="Lrule">Age Group</th>
                                       <th align="center">Dose (mg/kg)</th>
                                       <th align="left" styleCode="Rrule">Dose Interval</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="left" styleCode="Lrule">Infants less than 32 weeks GA and PNA less than 2 weeks</td>
                                       <td align="center" valign="top">20</td>
                                       <td align="left" styleCode="Rrule" valign="top">Every 12 hours</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Infants less than 32 weeks GA and PNA 2 weeks and older</td>
                                       <td align="center" valign="top">20</td>
                                       <td align="left" styleCode="Rrule" valign="top">Every 8 hours</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Infants 32 weeks and older GA and PNA less than 2 weeks</td>
                                       <td align="center" valign="top">20</td>
                                       <td align="left" styleCode="Rrule" valign="top">Every 8 hours</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule">Infants 32 weeks and older GA and PNA 2 weeks and older</td>
                                       <td align="center" valign="top">30</td>
                                       <td align="left" styleCode="Rrule" valign="top">Every 8 hours</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There is no experience in pediatric patients with renal impairment.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="34745c71-cff5-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation and Administration of Meropenem for Injection</title>
                     <effectiveTime value="20250505"/>
                     <component>
                        <section>
                           <id root="34745c71-cff6-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Important Administration Instructions:</content>
                              </paragraph>
                              <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.﻿</paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-cff7-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">For Intravenous Bolus Administration</content>
                              </paragraph>
                              <paragraph>Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see
 
  <linkHtml href="#Dose4">Table 4</linkHtml> below). Shake to dissolve and let stand until clear.

 </paragraph>
                              <paragraph>
                                 <content styleCode="bold">﻿Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials</content>
                              </paragraph>
                              <table ID="Dose4" width="75%">
                                 <col width="15%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th align="left" styleCode="Lrule">Vial Size</th>
                                       <th align="center">Amount of Diluent Added (mL)</th>
                                       <th align="center">Approximate Withdrawable Volume (mL)</th>
                                       <th align="center" styleCode="Rrule">Approximate Average Concentration (mg/mL)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="left" styleCode="Lrule">500 mg</td>
                                       <td align="center">10</td>
                                       <td align="center">10</td>
                                       <td align="center" styleCode="Rrule">50</td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule">1 gram</td>
                                       <td align="center">20</td>
                                       <td align="center">20</td>
                                       <td align="center" styleCode="Rrule">50</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph/>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-cff8-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">For Infusion</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid.</item>
                                 <item>Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid
  
   <content styleCode="italics">[</content>
                                    <content styleCode="italics">see
   
    <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and
   
    <linkHtml href="#S2.6">(2.6)</linkHtml>
                                    </content>
                                    <content styleCode="italics">]</content>.
 
  </item>
                                 <item>Do not use flexible container in series connections.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="34745c71-cff9-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Compatibility</title>
                     <text>
                        <paragraph>Compatibility of meropenem for injection with other drugs has not been established. Meropenem for injection should not be mixed with or physically added to solutions containing other drugs.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="34745c71-cffa-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Stability and Storage</title>
                     <text>
                        <paragraph>Freshly prepared solutions of meropenem for injection should be used. However, re-constituted solutions of meropenem for injection maintain satisfactory potency under the conditions described below. Solutions of intravenous meropenem for injection should not be frozen.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                     <component>
                        <section>
                           <id root="34745c71-cffb-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Intravenous Bolus Administration</content>
                              </paragraph>
                              <paragraph>Meropenem for injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of meropenem for injection) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F).</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-cffc-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Intravenous Infusion Administration</content>
                              </paragraph>
                              <paragraph>Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 15 hours at up to 5°C (41°F).</paragraph>
                              <paragraph>Solutions prepared for infusion (meropenem for injection concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Dextrose Injection 5% should be used immediately.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="34745c71-cffd-172a-e063-6394a90adc67"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Single dose clear glass vials of meropenem for injection containing 500 mg or 1 gram (as the trihydrate blended with anhydrous sodium carbonate for re-constitution) of sterile meropenem powder.</paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>500 mg Meropenem for Injection Vial (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                           <item>1 gram Meropenem for Injection Vial (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="34745c71-cffe-172a-e063-6394a90adc67"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Meropenem is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta (β)-lactams.</paragraph>
               </text>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Known hypersensitivity to product components or anaphylactic reactions to β-lactams. (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="34745c71-cfff-172a-e063-6394a90adc67"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250225"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>Severe cutaneous adverse reactions have been reported in patients receiving meropenem. (
  
     <linkHtml href="#L422f7323-6321-45a3-8e79-2f28a685fc66">5.2</linkHtml>)
 
    </item>
                           <item>Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue meropenem and initiate appropriate therapy. (
  
     <linkHtml href="#S5.2">5.3</linkHtml>)
 
    </item>
                           <item>Seizures and other adverse CNS experiences have been reported during treatment. (
  
     <linkHtml href="#L07abb379-fdc1-4af5-9808-cae4fc7b94bd">5.4</linkHtml>)
 
    </item>
                           <item>Co-administration of meropenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. (
  
     <linkHtml href="#S5.3">5.5</linkHtml>,
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs. (
  
     <linkHtml href="#S5.4">5.6</linkHtml>)
 
    </item>
                           <item>In patients with renal dysfunction, thrombocytopenia has been observed. (
  
     <linkHtml href="#S5.8">5.9</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="34745c71-d000-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with β-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens.</paragraph>
                        <paragraph>There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another β-lactam. Before initiating therapy with meropenem, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. If an allergic reaction to meropenem occurs, discontinue the drug immediately.</paragraph>
                     </text>
                     <effectiveTime value="20250225"/>
                  </section>
               </component>
               <component>
                  <section ID="L422f7323-6321-45a3-8e79-2f28a685fc66">
                     <id root="34745c71-d001-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Severe Cutaneous Adverse Reactions</title>
                     <text>
                        <paragraph>Severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalized exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem
 
  <content styleCode="italics">[</content>see Adverse Reactions (6.2)
 
  <content styleCode="italics">]</content>. If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.

 </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="34745c71-d002-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Rhabdomyolysis</title>
                     <text>
                        <paragraph>Rhabdomyolysis has been reported with the use of meropenem
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]
 
  </content>. If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine or elevated creatine phosphokinase are observed, discontinue meropenem and initiate appropriate therapy.

 </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="L07abb379-fdc1-4af5-9808-cae4fc7b94bd">
                     <id root="34754c92-cd42-7c0f-e063-6394a90a4d28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Seizure Potential</title>
                     <text>
                        <paragraph>Seizures and other adverse CNS experiences have been reported during treatment with meropenem. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and/or compromised renal function 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see 
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and 
   <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.
 </paragraph>
                        <paragraph>During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with the overall seizure rate being 0.7% (based on 20 patients with this adverse event). All meropenem-treated patients with seizures had pre-existing contributing factors. Among these are included prior history of seizures or CNS abnormality and concomitant medications with seizure potential. Dosage adjustment is recommended in patients with advanced age and/or adult patients with creatinine clearance of 50 mL/min or less 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see 
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.
 </paragraph>
                        <paragraph>Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity. Continue anti-convulsant therapy in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, evaluate neurologically, placed on anti-convulsant therapy if not already instituted, and re-examine the dosage of meropenem to determine whether it should be decreased or discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="34745c71-d004-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid</title>
                     <text>
                        <paragraph>The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. Consider administration of antibacterial drugs other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. If administration of meropenem is necessary, consider supplemental anti-convulsant therapy
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see
  
   <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="34745c71-d005-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Clostridioides difficile-associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including meropenem, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
 
  <content styleCode="italics">C. difficile</content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of
 
  <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

 </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against
 
  <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of
 
  <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.

 </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="34745c71-d006-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing meropenem in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="34745c71-d007-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Overgrowth of Nonsusceptible Organisms</title>
                     <text>
                        <paragraph>As with other broad-spectrum antibacterial drugs, prolonged use of meropenem may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient is essential. If superinfection does occur during therapy, appropriate measures should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="34751650-0c00-c0a4-e063-6294a90ab38f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Thrombocytopenia</title>
                     <text>
                        <paragraph>In patients with renal impairment, thrombocytopenia has been observed but no clinical bleeding reported 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see 
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, 
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, 
   <linkHtml href="#S8.5">Use In Specific Populations (8.5)</linkHtml> and 
  </content>
                           <content styleCode="italics">
                              <linkHtml href="#S8.6">(8.6)</linkHtml>, and 
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.
 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="34745c71-d009-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Potential for Neuromotor Impairment</title>
                     <text>
                        <paragraph>Alert patients receiving meropenem on an outpatient basis regarding adverse events such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that meropenem is well tolerated, advise patients not to operate machinery or motorized vehicles
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="34745c71-d00a-172a-e063-6394a90adc67"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following are discussed in greater detail in other sections of labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Severe Cutaneous Adverse Reactions
  
   <content styleCode="italics">[</content>see
  
   <linkHtml href="#L422f7323-6321-45a3-8e79-2f28a685fc66">Warnings and Precautions (5.2)</linkHtml>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Rhabdomyolysis
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Seizure Potential
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#L07abb379-fdc1-4af5-9808-cae4fc7b94bd">Warnings and Precautions (5.4)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.5)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridioides difficile</content>- associated Diarrhea
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.6)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Development of Drug-Resistant Bacteria
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.7)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Overgrowth of Nonsusceptible Organisms
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.6">Warnings and Precautions (5.8)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Thrombocytopenia
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.8">Warnings and Precautions (5.9)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Potential for Neuromotor Impairment
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250506"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (2% or less) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash. (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Savior Lifetec Corporation at 886-6-505-1200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="34745c71-d00b-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Adverse Reactions from Clinical Trials</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250506"/>
                     <component>
                        <section>
                           <id root="34745c71-d00c-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="underline">Adult Patients:</content>
                                 </content>
                              </paragraph>
                              <paragraph>During clinical investigations, 2904 immunocompetent adult patients were treated for non-CNS infections with meropenem (500 mg or 1 gram every 8 hours). Deaths in 5 patients were assessed as possibly related to meropenem; 36 (1.2%) patients had meropenem discontinued because of adverse events. Many patients in these trials were severely ill and had multiple background diseases, physiological impairments and were receiving multiple other drug therapies. In the seriously ill patient population, it was not possible to determine the relationship between observed adverse events and therapy with meropenem.</paragraph>
                              <paragraph>The following adverse reaction frequencies were derived from the clinical trials in the 2904 patients treated with meropenem.</paragraph>
                           </text>
                           <effectiveTime value="20250208"/>
                           <component>
                              <section ID="id_link_34887735-f59c-aa01-e063-6294a90af846">
                                 <id root="34887735-f59b-aa01-e063-6294a90af846"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Local Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Local adverse events that were reported with meropenem were as follows:</paragraph>
                                    <paragraph/>
                                    <paragraph>      Inflammation at the injection site       2.4%</paragraph>
                                    <paragraph>      Injection site reaction                          0.9%</paragraph>
                                    <paragraph>      Phlebitis/thrombophlebitis                  0.8%</paragraph>
                                    <paragraph>      Pain at the injection site                      0.4%</paragraph>
                                    <paragraph>      Edema at the injection site                  0.2%</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section ID="id_link_34755b59-148e-e540-e063-6294a90a9e9f">
                                 <id root="34755b59-148d-e540-e063-6294a90a9e9f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Systemic Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Systemic adverse events that were reported with meropenem occurring in greater than 1.0% of the patients were diarrhea (4.8%), nausea/vomiting (3.6%), headache (2.3%), rash (1.9%), sepsis (1.6%), constipation (1.4%), apnea (1.3%), shock (1.2%), and pruritus (1.2%).</paragraph>
                                    <paragraph>Additional systemic adverse events that were reported with meropenem and occurring in less than or equal to 1.0% but greater than 0.1% of the patients are listed below within each body system in order of decreasing frequency:</paragraph>
                                    <paragraph>Bleeding events were seen as follows: gastrointestinal hemorrhage (0.5%), melena (0.3%), epistaxis (0.2%), hemoperitoneum (0.2%).</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Body as a Whole</content>: pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, pelvic pain
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Cardiovascular</content>: heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension, syncope
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Digestive System</content>: oral moniliasis, anorexia, cholestatic jaundice/jaundice, flatulence, ileus, hepatic failure, dyspepsia, intestinal obstruction
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Hemic/Lymphatic</content>: anemia, hypochromic anemia, hypervolemia
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Metabolic/Nutritional</content>: peripheral edema, hypoxia
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Nervous System</content>: insomnia, agitation, delirium, confusion, dizziness, seizure, nervousness, paresthesia, hallucinations, somnolence, anxiety, depression, asthenia 
  <content styleCode="italics">[</content>
                                       <content styleCode="italics">see 
   <linkHtml href="#L07abb379-fdc1-4af5-9808-cae4fc7b94bd">Warnings and Precautions (5.4)</linkHtml> and 
   <linkHtml href="#S5.10">(5.10)</linkHtml>
                                       </content>
                                       <content styleCode="italics">]</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Respiratory</content>: respiratory disorder, dyspnea, pleural effusion, asthma, cough increased, lung edema
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Skin and Appendages</content>: urticaria, sweating, skin ulcer
 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Urogenital System</content>: dysuria, kidney failure, vaginal moniliasis, urinary incontinence
 </paragraph>
                                 </text>
                                 <effectiveTime value="20250208"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="34745c71-d00f-172a-e063-6394a90adc67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Adverse Laboratory Changes</content>
                                    </paragraph>
                                    <paragraph>Adverse laboratory changes that were reported and occurring in greater than 0.2% of the patients were as follows:</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Hepatic:</content>increased alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase, lactose dehydrogenase (LDH), and bilirubin

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Hematologic:</content>increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cell (WBC), shortened prothrombin time and shortened partial thromboplastin time, leukocytosis, hypokalemia

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Renal:</content>increased creatinine and increased blood urea nitrogen (BUN)

 </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Urinalysis:</content>presence of red blood cells

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250208"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="34745c71-d010-172a-e063-6394a90adc67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Complicated Skin and Skin Structure Infections</content>
                                    </paragraph>
                                    <paragraph>In a study of complicated skin and skin structure infections, the adverse reactions were similar to those listed above. The most common adverse events occurring in greater than 5% of the patients were: headache (7.8%), nausea (7.8%), constipation (7.0%), diarrhea (7.0%), anemia (5.5%), and pain (5.1%). Adverse events with an incidence of greater than 1%, and not listed above, include: pharyngitis, accidental injury, gastrointestinal disorder, hypoglycemia, peripheral vascular disorder, and pneumonia.</paragraph>
                                 </text>
                                 <effectiveTime value="20250208"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="L49cf5aa9-e190-4477-b7a8-1f40f9fde1aa">
                           <id root="347579ff-1026-8929-e063-6394a90aa497"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="bold">Patients with Renal Impairment:</content>
                                 </content>
                              </paragraph>
                              <paragraph>For patients with varying degrees of renal impairment, the incidence of heart failure, kidney failure, seizure and shock reported with meropenem, increased in patients with moderately severe renal impairment (creatinine clearance 10 to 26 mL/min) 
  <content styleCode="italics">[</content>
                                 <content styleCode="italics">see 
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, 
   <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>, 
   <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml> and  
   <linkHtml href="#S8.6">(8.6)</linkHtml>, and  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.
 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_34758b4b-a69a-9590-e063-6394a90a7085">
                           <id root="3488707a-b65a-3e7f-e063-6394a90a6c8f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">
                                    <content styleCode="bold">Pediatric Patients:</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Systemic and Local Adverse Reactions</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">﻿Pediatric Patients with Serious Bacterial Infections (excluding Bacterial Meningitis):</content>
                              </paragraph>
                              <paragraph>Meropenem was studied in 515 pediatric patients (3 months to less than 13 years of age) with serious bacterial infections (excluding meningitis, see next section) at dosages of 10 mg/kg to 20 mg/kg every 8 hours. The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse events reported as possibly, probably, or definitely related to meropenem and their rates of occurrence as follows:</paragraph>
                              <paragraph/>
                              <paragraph>      Diarrhea                               3.5%</paragraph>
                              <paragraph>      Rash                                    1.6%</paragraph>
                              <paragraph>      Nausea and Vomiting           0.8%</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="italics">﻿Pediatric Patients with Bacterial Meningitis:</content>
                              </paragraph>
                              <paragraph>Meropenem was studied in 321 pediatric patients (3 months to less than 17 years of age) with meningitis at a dosage of 40 mg/kg every 8 hours. The types of systemic and local adverse events seen in these patients are similar to the adults, with the most common adverse reactions reported as possibly, probably, or definitely related to meropenem and their rates of occurrence as follows:</paragraph>
                              <paragraph/>
                              <paragraph>Diarrhea 4.7%</paragraph>
                              <paragraph>Rash (mostly diaper area moniliasis) 3.1%</paragraph>
                              <paragraph>Oral Moniliasis 1.9%</paragraph>
                              <paragraph>Glossitis 1.0%</paragraph>
                              <paragraph/>
                              <paragraph>In the meningitis studies, the rates of seizure activity during therapy were comparable between patients with no CNS abnormalities who received meropenem and those who received comparator agents (either cefotaxime or ceftriaxone). In the meropenem treated group, 12/15 patients with seizures had late onset seizures (defined as occurring on day 3 or later) versus 7/20 in the comparator arm. The meropenem group had a statistically higher number of patients with transient elevation of liver enzymes.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">﻿Pediatric Patients (Neonates and Infants less than 3 months of Age):</content>
                              </paragraph>
                              <paragraph>Meropenem was studied in 200 neonates and infants less than 3 months of age. The study was open-label, uncontrolled, 98% of the infants received concomitant medications, and the majority of adverse events were reported in neonates less than 32 weeks gestational age and critically ill at baseline, making it difficult to assess the relationship of the adverse events to meropenem.</paragraph>
                              <paragraph>The adverse reactions seen in these patients that were reported and their rates of occurrence are as follows:</paragraph>
                              <paragraph/>
                              <paragraph>Convulsion 5.0%</paragraph>
                              <paragraph>Hyperbilirubinemia (conjugated) 4.5%</paragraph>
                              <paragraph>Vomiting 2.5%</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="italics">Adverse Laboratory Changes in Pediatric Patients:</content>
                              </paragraph>
                              <paragraph>Laboratory changes seen in the pediatric studies, including the meningitis studies, were similar to those reported in the adult studies.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="347512f9-a1b2-6092-e063-6394a90a07f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of meropenem. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Worldwide post-marketing adverse reactions not otherwise listed in the Adverse Reactions from Clinical Trials section of this prescribing information and reported as possibly, probably, or definitely drug related are listed within each body system in order of decreasing severity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">﻿Blood and Lymphatic System Disorders: </content>﻿agranulocytosis, neutropenia, and leukopenia; a positive direct or indirect Coombs test, and hemolytic anemia.
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">﻿Immune System Disorders: </content>angioedema.
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Skin and Subcutaneous Disorders: </content>Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme and acute generalized exanthematous pustulosis.
 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Musculoskeletal Disorders: </content>rhabdomyolysis.
 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="34745c71-d015-172a-e063-6394a90adc67"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Co-administration of meropenem with probenecid inhibits renal excretion of meropenem and is therefore not recommended. (
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
 
    </item>
                           <item>The concomitant use of meropenem and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. (
  
     <linkHtml href="#S5.3">5.5</linkHtml>,
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="34745c71-d016-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Probenecid</title>
                     <text>
                        <paragraph>Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem.  Co-administration of probenecid with meropenem is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="34745c71-d017-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Valproic Acid</title>
                     <text>
                        <paragraph>Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from
 
  <content styleCode="italics">in vitro </content>and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of meropenem is necessary, then supplemental anti-convulsant therapy should be considered
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.5)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="34745c71-d018-172a-e063-6394a90adc67"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Renal Impairment: Dose adjustment is necessary, if creatinine clearance is 50 mL/min or less. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>,
  
     <linkHtml href="#S8.6">8.6</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="34745c71-d019-172a-e063-6394a90adc67"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="34745c71-d01a-172a-e063-6394a90adc67"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are insufficient human data to establish whether there is a drug-associated risk of major birth defects or miscarriages with meropenem in pregnant women.</paragraph>
                              <paragraph>No fetal toxicity or malformations were observed in pregnant rats and Cynomolgus monkeys administered intravenous meropenem during organogenesis at doses up to 2.4 and 2.3 times the maximum recommended human dose (MRHD) based on body surface area comparison, respectively. In rats administered intravenous meropenem in late pregnancy and during the lactation period, there were no adverse effects on offspring at doses equivalent to approximately 3.2 times the MRHD based on body surface area comparison (see
 
  <content styleCode="italics">Data</content>).

 </paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Meropenem administered to pregnant rats during organogenesis (Gestation Day 6 to Gestation Day 17) in intravenous doses of 240, 500, and 750 mg/kg/day was associated with mild maternal weight loss at all doses, but did not produce malformations or fetal toxicity. The no-observed-adverse-effect-level (NOAEL) for fetal toxicity in this study was considered to be the high dose of 750 mg/kg/day (equivalent to approximately 2.4 times the MRHD of 1 gram every 8 hours based on body surface area comparison). Meropenem administered intravenously to pregnant Cynomolgus monkeys during organogenesis from Day 20 to 50 after mating at doses of 120, 240, and 360 mg/kg/day did not produce maternal or fetal toxicity at the NOAEL dose of 360 mg/kg/day (approximately 2.3 times the MRHD based on body surface area comparison).</paragraph>
                              <paragraph>In a peri-postnatal study in rats described in the published literature
 
  <sup>2</sup>, intravenous meropenem was administered to dams from Gestation Day 17 until Lactation Day 21 at doses of 240, 500, and 1000 mg/kg/day. There were no adverse effects in the dams and no adverse effects in the first-generation offspring (including developmental, behavioral, and functional assessments and reproductive parameters) except that female offspring exhibited lowered body weights which continued during gestation and nursing of the second-generation offspring. Second-generation offspring showed no meropenem-related effects. The NOAEL value was considered to be 1000 mg/kg/day (approximately 3.2 times the MRHD based on body surface area comparisons).

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="34745c71-d01b-172a-e063-6394a90adc67"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Meropenem has been reported to be excreted in human milk. No information is available on the effects of meropenem on the breast-fed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for meropenem and any potential adverse effects on the breast-fed child from meropenem or from the underlying maternal conditions.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="34745c71-d01c-172a-e063-6394a90adc67"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of meropenem have been established for pediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for pediatric patients of all ages with complicated intra-abdominal infections.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                     <component>
                        <section>
                           <id root="34745c71-d01d-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Skin and Skin Structure Infections</content>
                              </paragraph>
                              <paragraph>Use of meropenem in pediatric patients 3 months of age and older with complicated skin and skin structure infections is supported by evidence from an adequate and well-controlled study in adults and additional data from pediatric pharmacokinetics studies
 
  <content styleCode="italics">[</content>
                                 <content styleCode="italics">see
  
   <linkHtml href="#S1.3">Indications and Usage (1.3)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and 
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d01e-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Intra-abdominal Infections</content>
                              </paragraph>
                              <paragraph>Use of meropenem in pediatric patients 3 months of age and older with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from pediatric pharmacokinetics studies and controlled clinical trials in pediatric patients. Use of meropenem in pediatric patients less than 3 months of age with intra-abdominal infections is supported by evidence from adequate and well-controlled studies in adults with additional data from a pediatric pharmacokinetic and safety study
 
  <content styleCode="italics">[</content>
                                 <content styleCode="italics">see
  
   <linkHtml href="#S1.2">Indications and Usage (1.2)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and
  
   <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d01f-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Bacterial Meningitis</content>
                              </paragraph>
                              <paragraph>Use of meropenem in pediatric patients 3 months of age and older with bacterial meningitis is supported by evidence from adequate and well-controlled studies in the pediatric population
 
  <content styleCode="italics">[</content>
                                 <content styleCode="italics">see
  
   <linkHtml href="#S1.3">Indications and Usage (1.3)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                                 </content>,
 
  <content styleCode="italics">
                                    <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml> and 
  
   <linkHtml href="#S14.3">Clinical Studies (14.3)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="34745c71-d020-172a-e063-6394a90adc67"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects in clinical studies of meropenem, approximately 1100 (30%) were 65 years of age and older, while 400 (11%) were 75 years and older. Additionally, in a study of 511 patients with complicated skin and skin structure infections, 93 (18%) were 65 years of age and older, while 38 (7%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects; spontaneous reports and other reported clinical experience have not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Meropenem is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                        <paragraph>A pharmacokinetic study with meropenem in elderly patients has shown a reduction in the plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="3475b993-a6c4-a399-e063-6394a90a15a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Dosage adjustment is necessary in patients with creatinine clearance 50 mL/min or less 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see 
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>
                           </content>
                           <content styleCode="italics">, 
   <linkHtml href="#S5.8">Warnings and Precautions (5.9)</linkHtml>, and 
   <linkHtml href="#L5fee7f0d-8dfe-426a-bf00-eba72f07f417">Clinical Pharmacology (12.3)</linkHtml>] 
  </content>.
 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="34745c71-d022-172a-e063-6394a90adc67"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In mice and rats, large intravenous doses of meropenem (2200 mg/kg to 4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.</paragraph>
                  <paragraph>Intentional overdosing of meropenem is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function. The largest dose of meropenem administered in clinical trials has been 2 grams given intravenously every 8 hours. At this dosage, no adverse pharmacological effects or increased safety risks have been observed.</paragraph>
                  <paragraph>Limited postmarketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Consider symptomatic treatments. In individuals with normal renal function, rapid renal elimination takes place. Meropenem and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.</paragraph>
               </text>
               <effectiveTime value="20191201"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="34750615-a25d-5dbd-e063-6394a90ad0d4"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Meropenem for injection is a sterile, pyrogen-free, synthetic, carbapenem antibacterial for intravenous administration. It is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxilic acid trihydrate. Its empirical formula is C
  <sub>17</sub>H
  <sub>25</sub>N
  <sub>3</sub>O
  <sub>5</sub>S∙3H
  <sub>2</sub>O with a molecular weight of 437.52. Its structural formula is:
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Meropenem for injection is a white to pale yellow crystalline powder. The solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3.</paragraph>
                  <paragraph>Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.</paragraph>
                  <paragraph>When re-constituted as instructed, each 1 gram meropenem for injection vial will deliver 1 gram of meropenem and 90.2 mg of sodium as sodium carbonate (3.92 mEq). Each 500 mg meropenem for injection vial will deliver 500 mg meropenem and 45.1 mg of sodium as sodium carbonate (1.96 mEq) 
  <content styleCode="italics">[</content>
                     <content styleCode="italics">see 
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>
                     </content>
                     <content styleCode="italics">]</content>.
 </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="meropenem-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="34745c71-d024-172a-e063-6394a90adc67"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S12.1">
                     <id root="34745c71-d025-172a-e063-6394a90adc67"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Meropenem is an antibacterial drug
 
  <content styleCode="italics">[</content>
                           <content styleCode="italics">see
  
   <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
               <component>
                  <section ID="L104dce25-3920-4e8e-94c1-cb0634a6cba7">
                     <id root="34745c71-d026-172a-e063-6394a90adc67"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best correlate with efficacy in animal and in vitro models of infection.</paragraph>
                     </text>
                     <effectiveTime value="20250506"/>
                  </section>
               </component>
               <component>
                  <section ID="L5fee7f0d-8dfe-426a-bf00-eba72f07f417">
                     <id root="34745c71-d027-172a-e063-6394a90adc67"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="34745c71-d028-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Plasma Concentrations</content>
                              </paragraph>
                              <paragraph>At the end of a 30-minute intravenous infusion of a single dose of meropenem for injection in healthy volunteers, mean peak plasma concentrations of meropenem are approximately 23 mcg/mL (range 14 to 26) for the 500 mg dose and 49 mcg/mL (range 39-58) for the 1 gram dose. A 5-minute intravenous bolus injection of meropenem for injection in healthy volunteers results in mean peak plasma concentrations of approximately 45 mcg/mL (range 18 to 65) for the 500 mg dose and 112 mcg/mL (range 83 to 140) for the 1 gram dose.</paragraph>
                              <paragraph>Following intravenous doses of 500 mg, mean plasma concentrations of meropenem usually decline to approximately 1 mcg/mL at 6 hours after administration.</paragraph>
                              <paragraph>No accumulation of meropenem in plasma was observed with regimens using 500 mg administered every 8 hours or 1 gram administered every 6 hours in healthy volunteers with normal renal function.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_3474d4a6-7fe0-524b-e063-6394a90a99ed">
                           <id root="34884733-392f-1d97-e063-6394a90ad56e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The plasma protein binding of meropenem is approximately 2%.</paragraph>
                              <paragraph>After a single intravenous dose of meropenem, the highest mean concentrations of meropenem were found in tissues and fluids at 1 hour (0.5 hours to 1.5 hours) after the start of infusion, except where indicated in the tissues and fluids listed in Table 5 below.</paragraph>
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table 5: Meropenem Concentrations in Selected Tissues (Highest Concentrations Reported)</content>
                              </paragraph>
                              <table width="75%">
                                 <colgroup>
                                    <col align="left" valign="top" width="20%"/>
                                    <col align="center" valign="top" width="20%"/>
                                    <col align="center" valign="top" width="20%"/>
                                    <col align="center" valign="top" width="20%"/>
                                    <col align="center" valign="top" width="20%"/>
                                 </colgroup>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th align="center" styleCode="Lrule">Tissue</th>
                                       <th align="center">Intravenous. Dose (gram)</th>
                                       <th align="center">Number of Samples</th>
                                       <th align="center">Mean
     <br/>
			[mcg/mL or mcg/(gram)] 
     <footnote ID="t5n1">at 1 hour unless otherwise noted</footnote>
                                       </th>
                                       <th align="center" styleCode="Rrule">Range
     <br/>
			[mcg/mL or mcg/(gram)]
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td align="left" styleCode="Lrule">Endometrium</td>
                                       <td align="center">0.5</td>
                                       <td align="center">7</td>
                                       <td align="center">4.2</td>
                                       <td align="center" styleCode="Rrule">1.7-10.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Myometrium</td>
                                       <td align="center">0.5</td>
                                       <td align="center">15</td>
                                       <td align="center">3.8</td>
                                       <td align="center" styleCode="Rrule">0.4-8.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Ovary</td>
                                       <td align="center">0.5</td>
                                       <td align="center">8</td>
                                       <td align="center">2.8</td>
                                       <td align="center" styleCode="Rrule">0.8-4.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Cervix</td>
                                       <td align="center">0.5</td>
                                       <td align="center">2</td>
                                       <td align="center">7</td>
                                       <td align="center" styleCode="Rrule">5.4-8.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Fallopian tube</td>
                                       <td align="center">0.5</td>
                                       <td align="center">9</td>
                                       <td align="center">1.7</td>
                                       <td align="center" styleCode="Rrule">0.3-3.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Skin</td>
                                       <td align="center">0.5</td>
                                       <td align="center">22</td>
                                       <td align="center">3.3</td>
                                       <td align="center" styleCode="Rrule">0.5-12.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Interstitial fluid 
     <footnote ID="t5n2">obtained from blister fluid</footnote>
                                       </td>
                                       <td align="center">0.5</td>
                                       <td align="center">9</td>
                                       <td align="center">5.5</td>
                                       <td align="center" styleCode="Rrule">3.2-8.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Skin</td>
                                       <td align="center">1</td>
                                       <td align="center">10</td>
                                       <td align="center">5.3</td>
                                       <td align="center" styleCode="Rrule">1.3-16.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Interstitial fluid 
     <footnoteRef IDREF="t5n2"/>
                                       </td>
                                       <td align="center">1</td>
                                       <td align="center">5</td>
                                       <td align="center">26.3</td>
                                       <td align="center" styleCode="Rrule">20.9-37.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Colon</td>
                                       <td align="center">1</td>
                                       <td align="center">2</td>
                                       <td align="center">2.6</td>
                                       <td align="center" styleCode="Rrule">2.5-2.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Bile</td>
                                       <td align="center">1</td>
                                       <td align="center">7</td>
                                       <td align="center">14.6 (3 hours)</td>
                                       <td align="center" styleCode="Rrule">4-25.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Gall bladder</td>
                                       <td align="center">1</td>
                                       <td align="center">1</td>
                                       <td align="center">—</td>
                                       <td align="center" styleCode="Rrule">3.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Peritoneal fluid</td>
                                       <td align="center">1</td>
                                       <td align="center">9</td>
                                       <td align="center">30.2</td>
                                       <td align="center" styleCode="Rrule">7.4-54.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Lung</td>
                                       <td align="center">1</td>
                                       <td align="center">2</td>
                                       <td align="center">4.8 (2 hours)</td>
                                       <td align="center" styleCode="Rrule">1.4-8.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Bronchial mucosa</td>
                                       <td align="center">1</td>
                                       <td align="center">7</td>
                                       <td align="center">4.5</td>
                                       <td align="center" styleCode="Rrule">1.3-11.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Muscle</td>
                                       <td align="center">1</td>
                                       <td align="center">2</td>
                                       <td align="center">6.1 (2 hours)</td>
                                       <td align="center" styleCode="Rrule">5.3-6.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Fascia</td>
                                       <td align="center">1</td>
                                       <td align="center">9</td>
                                       <td align="center">8.8</td>
                                       <td align="center" styleCode="Rrule">1.5-20</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Heart valves</td>
                                       <td align="center">1</td>
                                       <td align="center">7</td>
                                       <td align="center">9.7</td>
                                       <td align="center" styleCode="Rrule">6.4-12.1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">Myocardium</td>
                                       <td align="center">1</td>
                                       <td align="center">10</td>
                                       <td align="center">15.5</td>
                                       <td align="center" styleCode="Rrule">5.2-25.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td align="left" styleCode="Lrule">CSF (inflamed)</td>
                                       <td align="center">20 mg/kg 
     <footnote ID="t5n3">in pediatric patients of age 5 month to 8 years</footnote>
                                          <br/>
			40 mg/kg 
     <footnote ID="t5n4">in pediatric patients of age 1 month to 15 years</footnote>
                                       </td>
                                       <td align="center">8
     <br/>
			5
    </td>
                                       <td align="center">1.1 (2 hours)
     <br/>
			3.3 (3 hours)
    </td>
                                       <td align="center" styleCode="Rrule">0.2-2.8
     <br/>
			0.9-6.5
    </td>
                                    </tr>
                                    <tr>
                                       <td align="left" styleCode="Lrule">CSF (uninflamed)</td>
                                       <td align="center">1</td>
                                       <td align="center">4</td>
                                       <td align="center">0.2 (2 hours)</td>
                                       <td align="center" styleCode="Rrule">0.1-0.3</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d02a-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d02b-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>There is one metabolite of meropenem that is microbiologically inactive.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d02c-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Excretion</content>
                              </paragraph>
                              <paragraph>Meropenem is primarily excreted unchanged by the kidneys. Approximately 70% (50% - 75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Fecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion. Urinary concentrations of meropenem in excess of 10 mcg/mL are maintained for up to 5 hours after a 500 mg dose.</paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d02d-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="34745c71-d02e-172a-e063-6394a90adc67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Pharmacokinetic studies with meropenem in patients with renal impairment have shown that the plasma clearance of meropenem correlates with creatinine clearance. Dosage adjustments are necessary in subjects with renal impairment (creatinine clearance 50 mL/min or less)
 
  <content styleCode="italics">[</content>
                                       <content styleCode="italics">see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and 
 
  </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#S8.6">Use In Specific Populations (8.6)</linkHtml>
                                       </content>
                                       <content styleCode="italics">]</content>.

 </paragraph>
                                    <paragraph>Meropenem is hemodialyzable. However, there is no information on the usefulness of hemodialysis to treat overdosage
 
  <content styleCode="italics">[</content>
                                       <content styleCode="italics">see
  
   <linkHtml href="#S10">Overdosage (10)</linkHtml>
                                       </content>
                                       <content styleCode="italics">]</content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="34745c71-d02f-172a-e063-6394a90adc67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>A pharmacokinetic study with meropenem in patients with hepatic impairment has shown no effects of liver disease on the pharmacokinetics of meropenem.</paragraph>
                                 </text>
                                 <effectiveTime value="20191201"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="34745c71-d030-172a-e063-6394a90adc67"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>A pharmacokinetic study with meropenem in elderly patients with renal impairment showed a reduction in plasma clearance of meropenem that correlates with age-associated reduction in creatinine clearance.</paragraph>
                                 </text>
                                 <effectiveTime value="20191201"/>
                              </section>
                           </component>
                           <component>
                              <section ID="id_link_3474e03e-880f-5721-e063-6394a90a1c6c">
                                 <id root="3474e03e-880e-5721-e063-6394a90a1c6c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of meropenem for injection IV, in pediatric patients 2 years of age or older, are similar to those in adults. The elimination half-life for meropenem was approximately 1.5 hours in pediatric patients of age 3 months to 2 years.</paragraph>
                                    <paragraph>The pharmacokinetics of meropenem in patients less than 3 months of age receiving combination antibacterial drug therapy are given below.</paragraph>
                                    <paragraph>
                                       <br/>
                                       <content styleCode="bold">Table 6: Meropenem Pharmacokinetic Parameters in Patients Less Than 3 Months of Age*</content>
                                    </paragraph>
                                    <table width="75%">
                                       <colgroup>
                                          <col align="left" valign="top" width="20%"/>
                                          <col align="center" valign="top" width="16%"/>
                                          <col align="center" valign="top" width="16%"/>
                                          <col align="center" valign="top" width="16%"/>
                                          <col align="center" valign="top" width="16%"/>
                                          <col align="center" valign="top" width="16%"/>
                                       </colgroup>
                                       <thead>
                                          <tr styleCode="First Last">
                                             <td align="left" styleCode="Lrule Rrule"/>
                                             <td align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">GA less than 32 weeks PNA less than 2 weeks</content>
                                                <br/>
                                                <content styleCode="bold">(20mg/kg every 12 hours)</content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">GA less than 32 weeks PNA 2 weeks or older</content>
                                                <br/>
                                                <content styleCode="bold">(20mg/kg every 8 hours)</content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">GA 32 weeks or older PNA less than 2 weeks</content>
                                                <br/>
                                                <content styleCode="bold">(20mg/kg every 8 hours)</content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">GA 32 weeks or older PNA 2 weeks or older</content>
                                                <br/>
                                                <content styleCode="bold">(30mg/kg every 8 hours)</content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule">
                                                <content styleCode="bold">Overall</content>
                                             </td>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule First">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">CL (L/h/kg)</content>
                                             </td>
                                             <td align="center" styleCode="Toprule Botrule Lrule Rrule">0.089</td>
                                             <td align="center" styleCode="Toprule Botrule Lrule Rrule">0.122</td>
                                             <td align="center" styleCode="Toprule Botrule Lrule Rrule">0.135</td>
                                             <td align="center" styleCode="Toprule Botrule Lrule Rrule">0.202</td>
                                             <td align="center" styleCode="Toprule Botrule Lrule Rrule">0.119</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">V (L/kg)</content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">0.489</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">0.467</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">0.463</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">0.451</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">0.468</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">AUC 
      <sub>0-24 </sub>(mcg-h/mL) 
     </content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">448</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">491</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">445</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">444</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">467</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">C 
      <sub>max </sub>(mcg/mL) 
     </content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">44.3</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">46.5</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">44.9</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">61</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">46.9</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">C 
      <sub>min </sub>(mcg/mL) 
     </content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">5.36</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">6.65</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">4.84</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">2.1</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">5.65</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td align="left" styleCode="Lrule Rrule Toprule Botrule">
                                                <content styleCode="bold">T 
      <sub>1/2</sub> (h) 
     </content>
                                             </td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">3.82</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">2.68</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">2.33</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">1.58</td>
                                             <td align="center" styleCode="Lrule Rrule Toprule Botrule">2.68</td>
                                          </tr>
                                          <tr>
                                             <td align="left" colspan="6" styleCode="Lrule Rrule">*Values are derived from a population pharmacokinetic analysis of sparse data</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph/>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d032-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                              <paragraph>Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. Following administration of probenecid with meropenem, the mean systemic exposure increased 56% and the mean elimination half-life increased 38%
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="34745c71-d033-172a-e063-6394a90adc67"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="34745c71-d034-172a-e063-6394a90adc67"/>
                           <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most gram-positive and gram-negative bacteria to bind penicillin-bindingprotein (PBP) targets. Meropenem binds to PBPs 2, 3 and 4 of
 
  <content styleCode="italics">Escherichia coli and Pseudomonas aeruginosa</content>; and PBPs 1, 2 and 4 of
 
  <content styleCode="italics">Staphylococcus aureus.</content>Bactericidal concentrations (defined as a 3 log
 
  <sub>10 </sub>reduction in cell counts within 12 hours to 24 hours) are typically 1 to 2 times the bacteriostatic concentrations of meropenem, with the exception of
 
  <content styleCode="italics">Listeria monocytogenes</content>, against which lethal activity is not observed.

 </paragraph>
                              <paragraph/>
                              <paragraph>Meropenem does not have
 
  <content styleCode="italics">in vitro </content>activity against methicillin-resistant
 
  <content styleCode="italics">Staphylococcus aureus </content>(MRSA) or methicillin-resistant
 
  <content styleCode="italics">Staphylococcus epidermidis </content>(MRSE).

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d035-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                              <paragraph>There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target PBPs, 3) increased expression of efflux pump components, and 4) production of antibacterial drug-destroying enzymes (carbapenemases, metallo-β-lactamases).</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d036-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Cross-resistance is sometimes observed with isolates resistant to other carbapenems.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d037-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Interaction with Other Antimicrobials</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro </content>tests show meropenem to act synergistically with aminoglycoside antibacterial drugs against some isolates of
 
  <content styleCode="italics">Pseudomonas aeruginosa</content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_34749661-1448-453f-e063-6294a90a080d">
                           <id root="3474ba14-da99-369c-e063-6394a90a73ed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Meropenem has been shown to be active against most isolates of the following microorganisms, both 
  <content styleCode="italics">in vitro </content>and in clinical infections 
  <content styleCode="italics">[</content>
                                 <content styleCode="italics">see</content>
                                 <content styleCode="italics">
                                    <linkHtml href="#S1">Indications and Usage (1)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.
 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Gram-positive bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Enterococcus faecalis </content>(vancomycin-susceptible isolates only)
  <br/>
                                 <content styleCode="italics">Staphylococcus aureus </content>(methicillin-susceptible isolates only)
  <br/>
                                 <content styleCode="italics">Streptococcus agalactiae</content>
                                 <br/>
                                 <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible isolates only)
  <br/>
                                 <content styleCode="italics">Streptococcus pyogenes</content>
                                 <br/>
Viridans group streptococci
 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Gram-negative bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Escherichia coli</content>
                                 <br/>
                                 <content styleCode="italics">Haemophilus influenzae</content>
                                 <br/>
                                 <content styleCode="italics">Klebsiella pneumoniae</content>
                                 <br/>
                                 <content styleCode="italics">Neisseria meningitidis</content>
                                 <br/>
                                 <content styleCode="italics">Proteus mirabilis</content>
                                 <br/>
                                 <content styleCode="italics">Pseudomonas aeruginosa</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Anaerobic bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides fragilis</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides thetaiotaomicron</content>
                                 <br/>
                                 <content styleCode="italics">Peptostreptococcus </content>species
 </paragraph>
                              <paragraph/>
                              <paragraph>The following 
  <content styleCode="italics">in vitro </content>data are available, but their clinical significance is unknown. At least 90% of the following bacteria exhibit an 
  <content styleCode="italics">in vitro </content>minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for meropenem against isolates of similar genus or organism group. However, the efficacy of meropenem in treating clinical infections caused by these bacteria have not been established in adequate and well-controlled clinical trials.
 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Gram-positive bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Staphylococcus epidermidis </content>(methicillin-susceptible isolates only)
 </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Gram-negative bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Aeromonas hydrophila</content>
                                 <br/>
                                 <content styleCode="italics">Campylobacter jejuni</content>
                                 <br/>
                                 <content styleCode="italics">Citrobacter freundii</content>
                                 <br/>
                                 <content styleCode="italics">Citrobacter koseri</content>
                                 <br/>
                                 <content styleCode="italics">Enterobacter cloacae</content>
                                 <br/>
                                 <content styleCode="italics">Hafnia alvei</content>
                                 <br/>
                                 <content styleCode="italics">Klebsiella oxytoca</content>
                                 <br/>
                                 <content styleCode="italics">Moraxella catarrhalis</content>
                                 <br/>
                                 <content styleCode="italics">Morganella morganii</content>
                                 <br/>
                                 <content styleCode="italics">Pasteurella multocida</content>
                                 <br/>
                                 <content styleCode="italics">Proteus vulgaris</content>
                                 <br/>
                                 <content styleCode="italics">Serratia marcescens</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Anaerobic bacteria</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides ovatus</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides uniformis</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides ureolyticus</content>
                                 <br/>
                                 <content styleCode="italics">Bacteroides vulgatus</content>
                                 <br/>
                                 <content styleCode="italics">Clostridium difficile</content>
                                 <br/>
                                 <content styleCode="italics">Clostridium perfringens</content>
                                 <br/>
                                 <content styleCode="italics">Eggerthella lenta</content>
                                 <br/>
                                 <content styleCode="italics">Fusobacterium</content>species
  <br/>
                                 <content styleCode="italics">Parabacteroides distasonis</content>
                                 <br/>
                                 <content styleCode="italics">Porphyromonas asaccharolytica</content>
                                 <br/>
                                 <content styleCode="italics">Prevotella bivia</content>
                                 <br/>
                                 <content styleCode="italics">Prevotella intermedia</content>
                                 <br/>
                                 <content styleCode="italics">Prevotella melaninogenica</content>
                                 <br/>
                                 <content styleCode="italics">Propionibacterium acnes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d039-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="34745c71-d03a-172a-e063-6394a90adc67"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20191201"/>
               <component>
                  <section ID="S13.1">
                     <id root="34745c71-d03b-172a-e063-6394a90adc67"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20191201"/>
                     <component>
                        <section>
                           <id root="34745c71-d03c-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Carcinogenesis:</content>
                              </paragraph>
                              <paragraph>Carcinogenesis studies have not been performed.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d03d-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Mutagenesis:</content>
                              </paragraph>
                              <paragraph>Genetic toxicity studies were performed with meropenem using the bacterial reverse mutation test, the Chinese hamster ovary HGPRT assay, cultured human lymphocytes cytogenic assay, and the mouse micronucleus test. There was no evidence of mutagenic potential found in any of these tests.</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="34745c71-d03e-172a-e063-6394a90adc67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Impairment of Fertility:</content>
                              </paragraph>
                              <paragraph>In fertility studies, intravenous meropenem was administered to male rats beginning 11 weeks before mating and throughout mating and to female rats from 2 weeks before mating through Gestation Day 7 at doses of 240, 500, and 1000 mg/kg/day. There was no evidence of impaired fertility at doses up to 1000 mg/kg/day (on the basis of body surface area comparison, approximately 3.2 times to the MRHD of 1 gram every 8 hours).</paragraph>
                           </text>
                           <effectiveTime value="20191201"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="34745c71-d03f-172a-e063-6394a90adc67"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20191201"/>
               <component>
                  <section ID="S14.1">
                     <id root="34745c71-d040-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Complicated Skin and Skin Structure Infections</title>
                     <text>
                        <paragraph>Adult patients with complicated skin and skin structure infections including complicated cellulitis, complex abscesses, perirectal abscesses, and skin infections requiring intravenous antimicrobials, hospitalization, and surgical intervention were enrolled in a randomized, multi-center, international, double-blind trial. The study evaluated meropenem at doses of 500 mg administered intravenously every 8 hours and imipenem-cilastatin at doses of 500 mg administered intravenously every 8 hours. The study compared the clinical response between treatment groups in the clinically evaluable population at the follow-up visit (test-of-cure). The trial was conducted in the United States, South Africa, Canada, and Brazil. At enrollment, approximately 37% of the patients had underlying diabetes, 12% had underlying peripheral vascular disease and 67% had a surgical intervention. The study included 510 patients randomized to meropenem and 527 patients randomized to imipenem-cilastatin. Two hundred and sixty one (261) patients randomized to meropenem and 287 patients randomized to imipenem-cilastatin were clinically evaluable. The success rates in the clinically evaluable patients at the follow-up visit were 86% (225/261) in the meropenem arm and 83% (238/287) in imipenem-cilastatin arm.</paragraph>
                        <paragraph>The success rates for the clinically evaluable population are provided in
 
  <content styleCode="bold">Table 7</content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7: Success Rates at Test-of-Cure Visit for Clinically Evaluable Population with Complicated Skin and Skin Structure Infections</content>
                        </paragraph>
                        <table width="75%">
                           <col width="40%" align="left" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <col width="30%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule First Last">
                                 <th align="left" styleCode="Lrule Rrule">Population</th>
                                 <th align="center" styleCode="Lrule Rrule"> Meropenem  n
    
     <footnote ID="t9n1">n = number of patients with satisfactory response.</footnote>/N
    
     <footnote ID="t9n2">N = number of patients in the clinically evaluable population or respective subgroup within treatment groups.</footnote>(%)
   
    </th>
                                 <th align="center" styleCode="Lrule Rrule">Imipenem-cilastatin n
    
     <footnoteRef IDREF="t9n1"/>/N
    
     <footnoteRef IDREF="t9n2"/>(%) 
   
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule">Total</td>
                                 <td align="center">225/261 (86)</td>
                                 <td align="center" styleCode="Rrule">238/287 (83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">Diabetes mellitus</td>
                                 <td align="center">83/97 (86)</td>
                                 <td align="center" styleCode="Rrule">76/105 (72)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">No diabetes mellitus</td>
                                 <td align="center">142/164 (87)</td>
                                 <td align="center" styleCode="Rrule">162/182 (89)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">Less than 65 years of age</td>
                                 <td align="center">190/218 (87)</td>
                                 <td align="center" styleCode="Rrule">205/241 (85)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">65 years of age or older</td>
                                 <td align="center">35/43 (81)</td>
                                 <td align="center" styleCode="Rrule">33/46 (72)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">Men</td>
                                 <td align="center">130/148 (88)</td>
                                 <td align="center" styleCode="Rrule">137/172 (80)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule">Women</td>
                                 <td align="center">95/113 (84)</td>
                                 <td align="center" styleCode="Rrule">101/115 (88)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The clinical efficacy rates by pathogen are provided in Table 8. The values represent the number of patients clinically cured/number of clinically evaluable patients at the post-treatment follow-up visit, with the percent cure in parentheses (Fully Evaluable analysis set).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 8: Clinical Efficacy Rate by Pathogen for Clinically Evaluable Population</content>
                        </paragraph>
                        <table width="75%">
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="First Last">
                                 <th align="left" styleCode="Lrule" valign="middle">MICROORGANISMS
    
     <footnote ID="t10f1">Patients may have more than one pretreatment pathogen.</footnote>
                                 </th>
                                 <th align="center" valign="middle">Meropenem  n
    
     <footnote ID="t10f2">n = number of patients with satisfactory response.</footnote>/N
    
     <footnote ID="t10f3">N = number of patients in the clinically evaluable population or subgroup within treatment groups.</footnote>(%)
    
     <footnote ID="t10f4">% = Percent of satisfactory clinical response at follow-up evaluation.</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule" valign="middle">Imipenem-cilastatin n
    
     <footnoteRef IDREF="t10f2"/>/N
    
     <footnoteRef IDREF="t10f3"/>(%)
    
     <footnoteRef IDREF="t10f4"/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td colspan="3" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gram-positive aerobes</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Staphylococcus aureus,</content>methicillin susceptible
   
    </td>
                                 <td align="center">82/88 (93)</td>
                                 <td align="center" styleCode="Rrule">84/100 (84)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Streptococcus pyogenes</content>(Group A)
   
    </td>
                                 <td align="center">26/29 (90)</td>
                                 <td align="center" styleCode="Rrule">28/32 (88)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Streptococcus agalactiae</content>(Group B)
   
    </td>
                                 <td align="center">12/17 (71)</td>
                                 <td align="center" styleCode="Rrule">16/19 (84)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </td>
                                 <td align="center">9/12 (75)</td>
                                 <td align="center" styleCode="Rrule">14/20 (70)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">Viridans group streptococci</td>
                                 <td align="center">11/12 (92)</td>
                                 <td align="center" styleCode="Rrule">5/6 (83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gram-negative aerobes</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Escherichia coli</content>
                                 </td>
                                 <td align="center">12/15 (80)</td>
                                 <td align="center" styleCode="Rrule">15/21 (71)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Pseudomonas aeruginosa</content>
                                 </td>
                                 <td align="center">11/15 (73)</td>
                                 <td align="center" styleCode="Rrule">13/15 (87)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Proteus mirabilis</content>
                                 </td>
                                 <td align="center">11/13 (85)</td>
                                 <td align="center" styleCode="Rrule">6/7 (86)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" align="left" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anaerobes</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Bacteroides fragilis</content>
                                 </td>
                                 <td align="center">10/11 (91)</td>
                                 <td align="center" styleCode="Rrule">9/10 (90)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">Peptostreptococcus</content>species
   
    </td>
                                 <td align="center">10/13 (77)</td>
                                 <td align="center" styleCode="Rrule">14/16 (88)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The proportion of patients who discontinued study treatment due to an adverse event was similar for both treatment groups (meropenem, 2.5% and imipenem-cilastatin, 2.7%).</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="34745c71-d041-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Complicated Intra-Abdominal Infections</title>
                     <text>
                        <paragraph>One controlled clinical study of complicated intra-abdominal infection was performed in the United States where meropenem was compared with clindamycin/tobramycin. Three controlled clinical studies of complicated intra-abdominal infections were performed in Europe; meropenem was compared with imipenem (two trials) and cefotaxime/metronidazole (one trial).</paragraph>
                        <paragraph>Using strict evaluability criteria and microbiologic eradication and clinical cures at follow-up which occurred 7 or more days after completion of therapy, the presumptive microbiologic eradication/clinical cure rates and statistical findings are provided in Table 9:</paragraph>
                        <paragraph>
                           <content styleCode="bold">﻿Table 9: Presumptive Microbiologic Eradication and Clinical Cure Rates at Test-of-Cure Visit in the Evaluable Population with Complicated Intra-Abdominal Infection</content>
                        </paragraph>
                        <table width="75%">
                           <col width="20%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <thead>
                              <tr styleCode="First Last">
                                 <th align="center" styleCode="Lrule">Treatment Arm</th>
                                 <th align="center">No. evaluable/No. enrolled 
     <br/>  (%)
    </th>
                                 <th align="center">Microbiologic Eradication Rate</th>
                                 <th align="center">Clinical Cure Rate</th>
                                 <th align="center" styleCode="Rrule">Outcome</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule">meropenem</td>
                                 <td align="center">146/516 
     <br/>  (28%)
    </td>
                                 <td align="center">98/146 
     <br/>  (67%)
    </td>
                                 <td align="center">101/146 
     <br/>  (69%)
    </td>
                                 <td align="left" styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">imipenem</td>
                                 <td align="center">65/220 
     <br/>  (30%)
    </td>
                                 <td align="center">40/65 
     <br/>  (62%)
    </td>
                                 <td align="center">42/65 
     <br/>  (65%)
    </td>
                                 <td align="left" styleCode="Rrule">meropenem equivalent to control</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">cefotaxime/metronidazole</td>
                                 <td align="center">26/85 
     <br/>  (30%)
    </td>
                                 <td align="center">22/26 
     <br/>  (85%)
    </td>
                                 <td align="center">22/26 
     <br/>  (85%)
    </td>
                                 <td align="left" styleCode="Rrule">meropenem not equivalent to control</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule">clindamycin/tobramycin</td>
                                 <td align="center">50/212 
     <br/>  (24%)
    </td>
                                 <td align="center">38/50 
     <br/>  (76%)
    </td>
                                 <td align="center">38/50 
     <br/>  (76%)
    </td>
                                 <td align="left" styleCode="Rrule">meropenem equivalent to control</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The finding that meropenem was not statistically equivalent to cefotaxime/metronidazole may have been due to uneven assignment of more seriously ill patients to the meropenem arm. Currently there is no additional information available to further interpret this observation.</paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="34745c71-d042-172a-e063-6394a90adc67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Bacterial Meningitis</title>
                     <text>
                        <paragraph>Four hundred forty-six patients (397 pediatric patients 3 months to less than 17 years of age) were enrolled in 4 separate clinical trials and randomized to treatment with meropenem (n=225) at a dose of 40 mg/kg every 8 hours or a comparator drug, i.e., cefotaxime (n=187) or ceftriaxone (n=34), at the approved dosing regimens. A comparable number of patients were found to be clinically evaluable (ranging from 61-68%) and with a similar distribution of pathogens isolated on initial CSF culture.</paragraph>
                        <paragraph>Patients were defined as clinically not cured if any one of the following three criteria were met:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>At the 5 to 7 week post-completion of therapy visit, the patient had any one of the following: moderate to severe motor, behavior or development deficits, hearing loss of greater than 60 decibels in one or both ears, or blindness.</item>
                           <item>During therapy the patient's clinical status necessitated the addition of other antibacterial drugs.</item>
                           <item>Either during or post-therapy, the patient developed a large subdural effusion needing surgical drainage, or a cerebral abscess, or a bacteriologic relapse.</item>
                        </list>
                        <paragraph>Using the definition, the following efficacy rates were obtained, per organism (noted in
 
  <content styleCode="bold">Table 10</content>). The values represent the number of patients clinically cured/number of clinically evaluable patients, with the percent cure in parentheses.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">﻿Table 10: Efficacy rates by Pathogen in the Clinically Evaluable Population with Bacterial Meningitis</content>
                        </paragraph>
                        <table width="75%">
                           <col width="34%" align="left" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="First Last">
                                 <th align="center" styleCode="Lrule">MICROORGANISMS</th>
                                 <th align="center">Meropenem</th>
                                 <th align="center" styleCode="Rrule">COMPARATOR</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">S. pneumoniae</content>
                                 </td>
                                 <td align="center">17/24 (71)</td>
                                 <td align="center" styleCode="Rrule">19/30 (63)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">H. influenzae</content>(+)
    
     <footnote ID="t11f1">(+) β-lactamase-producing</footnote>
                                 </td>
                                 <td align="center">8/10 (80)</td>
                                 <td align="center" styleCode="Rrule">6/6 (100)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">H. influenzae</content>(-/NT)
    
     <footnote ID="t11f2">(-/NT) non-β-lactamase-producing or not tested</footnote>
                                 </td>
                                 <td align="center">44/59 (75)</td>
                                 <td align="center" styleCode="Rrule">44/60 (73)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">
                                    <content styleCode="italics">N. meningitidis</content>
                                 </td>
                                 <td align="center">30/35 (86)</td>
                                 <td align="center" styleCode="Rrule">35/39 (90)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule">Total (including others)</td>
                                 <td align="center">102/131 (78)</td>
                                 <td align="center" styleCode="Rrule">108/140 (77)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Sequelae were the most common reason patients were assessed as clinically not cured.</paragraph>
                        <paragraph>Five patients were found to be bacteriologically not cured, 3 in the comparator group (1 relapse and 2 patients with cerebral abscesses) and 2 in the meropenem group (1 relapse and 1 with continued growth of
 
  <content styleCode="italics">Pseudomonas aeruginosa</content>).

 </paragraph>
                        <paragraph>With respect to hearing loss, 263 of the 271 evaluable patients had at least one hearing test performed post-therapy. The following
 
  <content styleCode="bold">Table 11</content> shows the degree of hearing loss between the meropenem-treated patients and the comparator-treated patients.

 </paragraph>
                        <paragraph>
                           <content styleCode="bold">﻿Table 11: Hearing Loss at Post-Therapy in the Evaluable Population Treated with Meropenem</content>
                        </paragraph>
                        <table width="75%">
                           <col width="40%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="First Last">
                                 <th align="center" styleCode="Lrule">Degree of Hearing Loss (in one or both ears)</th>
                                 <th align="center">Meropenem 
     <br/>  n = 128
    </th>
                                 <th align="center" styleCode="Rrule">Comparator 
     <br/>  n = 135
    </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule">No loss</td>
                                 <td align="center">61%</td>
                                 <td align="center" styleCode="Rrule">56%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">20-40 decibels</td>
                                 <td align="center">20%</td>
                                 <td align="center" styleCode="Rrule">24%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule">Greater than 40-60 decibels</td>
                                 <td align="center">8%</td>
                                 <td align="center" styleCode="Rrule">7%</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule">Greater than 60 decibels</td>
                                 <td align="center">9%</td>
                                 <td align="center" styleCode="Rrule">10%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="34745c71-d043-172a-e063-6394a90adc67"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Cockcroft DW, MH Gault, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16:31-41.</item>
                     <item>Kawamura S, AW Russell, SJ Freeman, and RA Siddall, 1992, Reproductive and Developmental Toxicity of Meropenem in Rats, Chemotherapy, 40:S238-250.</item>
                  </list>
               </text>
               <effectiveTime value="20191201"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="34745c71-d044-172a-e063-6394a90adc67"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20191201"/>
               <component>
                  <section>
                     <id root="34745c71-d045-172a-e063-6394a90adc67"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Meropenem for injection is supplied in 20 mL and 30 mL injection vials containing sufficient meropenem to deliver 500 mg or 1 gram for intravenous administration, respectively. The dry powder should be stored at controlled room temperature 20º to 25ºC (68º to 77ºF) [see USP]. 
  <br/>  500 mg Injection Vial (NDC 0781-3000-94) and packaged in cartons of 10 vials (NDC 0781-3000-95) and cartons of 25 vials (NDC 0781-3000-96). 
  <br/>  1 gram Injection Vial (NDC 0781-3098-94) and packaged in cartons of 10 vials (NDC 0781-3098-95) and cartons of 25 vials (NDC 0781-3098-96).
 </paragraph>
                     </text>
                     <effectiveTime value="20191201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="34745c71-d046-172a-e063-6394a90adc67"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Counsel patients that antibacterial drugs including meropenem for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When meropenem for injection is prescribed to treat a bacterial infection, tell patients that although it is common to feel better early in the course of therapy, take the medication exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by meropenem for injection or other antibacterial drugs in the future.</item>
                     <item>Counsel patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.6)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>.
 
  </item>
                     <item>Counsel patients to inform their physician if they are taking valproic acid or divalproex sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with meropenem for injection. If treatment with meropenem for injection is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat seizures may be needed
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.5)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>.
 
  </item>
                     <item>Patients receiving meropenem for injection on an outpatient basis must be alerted of adverse events such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that meropenem for injection is well tolerated, patients should not operate machinery or motorized vehicles
  
   <content styleCode="italics">[</content>
                        <content styleCode="italics">see
   
    <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>.
 
  </item>
                  </list>
               </text>
               <effectiveTime value="20250208"/>
            </section>
         </component>
         <component>
            <section ID="id_link_2f04617e-0c51-9f97-e063-6294a90a73c4">
               <id root="3475d00b-15fc-af95-e063-6394a90a78f0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:
  <br/>
Savior Lifetec Corporation
  <br/>
4F., No. 12 &amp; 16, Chuangye Rd., Xinshi Dist., Tainan City 74144, Taiwan
  <br/>
for Sandoz Inc., Princeton, NJ 08540
 </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>975048-V06</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="id_link_1323cbbc-d9dc-3bea-e063-6394a90adff1">
               <id root="34747e68-66b6-23c5-e063-6294a90a4ce2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC </content>0781-3000-95
 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Meropenem for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mg per vial
   <br/>
Meropenem Equivalent
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">For Intravenous Use Only
    <br/>
Discard unused portion
   </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only
   <br/>
10 x 500 mg Single Dose Vials
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SANDOZ</content>
                     <br/>
A Novartis Division
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_1323a739-1bcd-b7ed-e063-6294a90aa2c9"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_1323a739-1bcd-b7ed-e063-6294a90aa2c9">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="meropenem-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_1323d22d-b0ea-14bb-e063-6294a90a0b02">
               <id root="3474882a-63bf-3c8c-e063-6294a90ac46e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 gram Vial Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC </content>0781-3098-95
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Meropenem for Injection, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 gram per vial
   <br/>
Meropenem Equivalent
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">For Intravenous Use Only
    <br/>
Discard unused portion
   </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only
   <br/>
10 x 1 gram Single Dose Vials
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">SANDOZ</content>
                     <br/>
A Novartis Division
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_1323cede-291a-d2b3-e063-6294a90ac715"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_1323cede-291a-d2b3-e063-6294a90ac715">
                     <text>PRINCIPAL DISPLAY PANEL - 1 g Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="meropenem-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L4770043f-266c-4694-84c5-175e9dbea35f">
               <id root="34745c71-d04a-172a-e063-6394a90adc67"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC </content>0781-3000-94

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Meropenem for Injection, USP</content>
                  </paragraph>
                  <paragraph>500 mg per vial 
  <br/>
                     <content styleCode="bold">Meropenem Equivalent</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only</content>
                     <br/>  Contents are Sterile

 </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">SANDOZ</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L9aea03be-53f9-43dd-825b-5bdf2138a21d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="L9aea03be-53f9-43dd-825b-5bdf2138a21d">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="meropenem-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L08dc61f8-3ddd-4e11-9f9e-df2dad02b40b">
               <id root="3474882a-63c0-3c8c-e063-6294a90ac46e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 gram Vial Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC </content>0781-3098-94
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Meropenem for Injection, USP</content>
                  </paragraph>
                  <paragraph>1 gram per vial
  <br/>
                     <content styleCode="bold">Meropenem Equivalent</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use Only</content>
                     <br/>
Contents are Sterile
 </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">SANDOZ</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="L0934c978-f009-4f32-b201-745732f0e728"/>
                     </content>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="L0934c978-f009-4f32-b201-745732f0e728">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="meropenem-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>